PHBI Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Pharmagreen Biotech, Inc.'s net margin of 42.95%. Pharmagreen Biotech, Inc.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Pharmagreen Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 8.93%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than Pharmagreen Biotech, Inc., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than Pharmagreen Biotech, Inc..

Pharmagreen Biotech, Inc. has a beta of 1.605, which suggesting that the stock is 60.458% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.187%.

Pharmagreen Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmagreen Biotech, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pharmagreen Biotech, Inc. quarterly revenues are $300, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Pharmagreen Biotech, Inc.'s net income of $45.6K is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Pharmagreen Biotech, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmagreen Biotech, Inc. is 754.14x versus 8.12x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Edesa Biotech, Inc. has a net margin of -- compared to Pharmagreen Biotech, Inc.'s net margin of --. Pharmagreen Biotech, Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Pharmagreen Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 643.09%. Given that Edesa Biotech, Inc. has higher upside potential than Pharmagreen Biotech, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Pharmagreen Biotech, Inc..

Pharmagreen Biotech, Inc. has a beta of 1.605, which suggesting that the stock is 60.458% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.133, suggesting its less volatile than the S&P 500 by 86.677%.

Pharmagreen Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmagreen Biotech, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Pharmagreen Biotech, Inc. quarterly revenues are $300, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Pharmagreen Biotech, Inc.'s net income of $45.6K is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Pharmagreen Biotech, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmagreen Biotech, Inc. is 754.14x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to Pharmagreen Biotech, Inc.'s net margin of --. Pharmagreen Biotech, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Pharmagreen Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 475.23%. Given that Oncolytics Biotech, Inc. has higher upside potential than Pharmagreen Biotech, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Pharmagreen Biotech, Inc..

Pharmagreen Biotech, Inc. has a beta of 1.605, which suggesting that the stock is 60.458% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.717%.

Pharmagreen Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmagreen Biotech, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Pharmagreen Biotech, Inc. quarterly revenues are $300, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Pharmagreen Biotech, Inc.'s net income of $45.6K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Pharmagreen Biotech, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmagreen Biotech, Inc. is 754.14x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -- compared to Pharmagreen Biotech, Inc.'s net margin of -163.68%. Pharmagreen Biotech, Inc.'s return on equity of -- beat Venus Concept, Inc.'s return on equity of -1236.95%.

Pharmagreen Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 7571.05%. Given that Venus Concept, Inc. has higher upside potential than Pharmagreen Biotech, Inc., analysts believe Venus Concept, Inc. is more attractive than Pharmagreen Biotech, Inc..

Pharmagreen Biotech, Inc. has a beta of 1.605, which suggesting that the stock is 60.458% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.041, suggesting its less volatile than the S&P 500 by 104.127%.

Pharmagreen Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharmagreen Biotech, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

Pharmagreen Biotech, Inc. quarterly revenues are $300, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. Pharmagreen Biotech, Inc.'s net income of $45.6K is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, Pharmagreen Biotech, Inc.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharmagreen Biotech, Inc. is 754.14x versus 0.03x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.